Interview: Prof. Dr. Murat Özgören – Vice-Rector, Dokuz Eylül…
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
Dokuz Eylül Health Technopark DEPARK
The first thematic health technopark in Turkey that is fully integrated with hospital, research centers and medical schools. It is an ideal location for biotech and medical device companies inb Turkey for R&D, product development and soft-landing. DEPARK has started medical technopark services at its mother building ZEYTIN. The name zeytin refers to olives and it stands for 3500 years lifespan of olive trees while still producing olives. It also refers to natural health remedies that are attached to the olive (e.g. as in the movie Lorenzo’s Oil). There is a specifically medicine oriented technology transfer office called DETTO (Dokuz Eylül Technology Transfer Office). It has a wide variety of services from international soft landing, tax and law support, IP rights management, incubation, technical consultancy, funding, clinical trials, pre-clinical consultation to marketing and guidance for international partnering. The hosting university, Dokuz Eylül University, has 14 faculties (app 67,000 students) to support the larger ecosystem for a wide range of activities and research. The ecosystem includes a university hospital over 1,100 beds, medical school, medical graduate study programs, medical research institutes (ie oncology, genome etc), nearly 1,000 academics, health technologies accelerator, associate service study programs like nursing, health technicians, sports technologies, physiotherapy center, medical devices calibration center and home-care research center.
BioIzmir
BioIzmir is an international gateway project for creating a one-stop-shop ecosystem for biotech and medical devices. It is located within a health technopark (DEPARK) embedded into a hospital complex.
From design to manufacturing, process to IPR rights this will be a critical partner for companies and development/tech transfer organizations. Izmir Health Technologies Development and Accelerator Center will serve as a hub of the essential elements known in medical circle as “from the laboratory bench to the patient’s bedside”. The structure of the Center will provide “one-stop-shop” aimed to establish Izmir as the intersection of health enterprise and innovation in regional, national and international contexts. The activities within the scope of the project will create an eco system in which integration occurs between the industry and the dynamics of R&D and innovation.
iBG-izmir
Dokuz Eylul University Izmir Biomedicine and Genome Center (iBG-izmir) is developed within “Bioİzmir” Science and Technology Park, which is the result of the innovative partnership of DEU Health Campus, the Faculty of Medicine & University Hospital and the Health Themed Technopark (DEPARK). iBG is the first such regional hub, with headquarters in Izmir, Turkey’s third largest city and a critical locomotive for growing Turkish economy, particularly within the health sector. iBG’s vision is to establish a most prominent center for health and life sicences in South-West Europe and MENA countries in a 10 years period. This comprehensive regional hub will be multidisciplinary in approach and shall bring molecular biology, genetics, medicine, pharmaceutical sciences, bioengineering, computer engineering and many other fields together. iBG-izmir will open its doors in 09-10 Sep 2015 with including Nobel session and reception.
Contact
Dokuz Eylül Üniversitesi İnciraltı Yerleşkesi Balçova
35340 İzmir Türkiye
Tel: +90 (232) 412 80 00
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
Keyman’s general manager discusses his firm’s development efforts towards vaccine production, in conjunction with TUBITAK and Hacettepe University, and their geographic expansion into Africa, Latin America, and Southeast Asia. Please…
A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in…
Imuneks is currently operating in the OTC market, but with three supergeneric products ready to market on the RX side, the firm has the potential to soon become one of…
Recordati’s South East regional VP, based in Istanbul, discusses Recordati Turkey’s key role as a manufacturing hub for Recordati, the importance of the Turkish market (fourth largest globally for the…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted…
The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great…
Turkey’s leading pharmaceutical company is in the process of developing production facilities abroad, and it has just begun construction of a USD 100 million biotech facility; CEO Süha Taşpolatoğlu believes…
The leadership of Turkey’s newest major pharmaceutical player, Pharmactive, discuss the firm’s two pronged growth strategy, detailing their own sales objectives and prospects, as well as the opportunities that they…
Polifarma is Turkey’s largest producer of basic parenteral IV solutions with a 41 percent market share the country and growing exports across the region. According to the Chairman and CEO…
See our Cookie Privacy Policy Here